UBS Group’s Lux Health Tech Acquisition Corp. Class A Common Stock LUXA Stock Holding History

UBS Group’s Portfolio LUXA Stock Details LUXA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4,781	Closed	-$48K	–	11893
2022 Q3	$48K	Sell	4,781 -1,377	-22%	-$13.7K	﹤0.01%	6395
2022 Q2	$61K	Sell	6,158 -798	-11%	-$7.88K	﹤0.01%	5775
2022 Q1	$68K	Buy	6,956 +2,903	+72%	+$28.5K	﹤0.01%	6209
2021 Q4	$39K	Sell	4,053 -199	-5%	-$1.96K	﹤0.01%	7165
2021 Q3	$41K	Sell	4,252 -1,900	-31%	-$18.7K	﹤0.01%	6514
2021 Q2	$61K	Sell	6,152 -806	-12%	-$8.11K	﹤0.01%	6259
2021 Q1	$71K	Buy	+6,958	New	+$77.2K	﹤0.01%	6227

UBS Group's LUXA Position: Q4 2022 in Review

UBS Group sold out of Lux Health Tech Acquisition Corp. Class A Common Stock (LUXA) in Q4 2022, closing a stake of 4,781 shares — an estimated $48K sold.

UBS Group first reported a position in LUXA in Q1 2021 and held it in 7 quarters. The position peaked at $71K in Q1 2021. 0 funds tracked by Wall St. Rank hold LUXA as of Q4 2022.

UBS Group reported no remaining Lux Health Tech Acquisition Corp. Class A Common Stock position as of Q4 2022 after selling out during the quarter.
UBS Group sold 4,781 Lux Health Tech Acquisition Corp. Class A Common Stock shares in Q4 2022, an estimated $48K.
UBS Group first reported a position in Lux Health Tech Acquisition Corp. Class A Common Stock in Q1 2021 and held it in 7 quarters.
UBS Group's Lux Health Tech Acquisition Corp. Class A Common Stock position peaked at $71K in Q1 2021.
0 funds tracked by Wall St. Rank held Lux Health Tech Acquisition Corp. Class A Common Stock as of Q4 2022.

Based on UBS Group's 13F filing for Q4 2022, filed 8 Feb 2023.